DR LAL Rating
JPMORGAN ON DR LAL : 24.05.2021
* MAINTAIN UNDERWEIGHT TARGET: 2,200
* JPMorgan maintains UNDERWEIGHT stance on Dr Lal PathLabs, target at Rs 2,200/sh
* COVID Volumes Continue To Surprise On The Upside
* Risk To Core Margin From Rest Of India Remains
* Non-COVID Growth Is A Good Sign & Provides Confidence On Volume Trend
* Valuations Look Stretched At Current Levels
GS ON DR LAL PATHLABS
* MAINTAIN BUY TARGET: 3,210
* Goldman Sachs maintains BUY call on Dr Lal PathLabs, target at Rs 3,210/sh
* Reference Lab Expansion On Track
* Lockdowns Could Delay Some Non-COVID Testing Demand
* Like Co's Ability To Execute On Pent-up Diagnostic Testing Demand
* Goldman Sachs maintains BUY call on Dr Lal PathLabs, target at Rs 3,210/sh
* Reference Lab Expansion On Track
* Lockdowns Could Delay Some Non-COVID Testing Demand
* Like Co's Ability To Execute On Pent-up Diagnostic Testing Demand
